+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effects of vascular endothelial growth factor on acute myelogenous leukemia blasts



Effects of vascular endothelial growth factor on acute myelogenous leukemia blasts



Journal of HematoTherapy and Stem Cell Research 10(1): 81-93



Vascular endothelial growth factor (VEGF) and its specific receptors are expressed by various malignant cells, including acute myelogenous leukemia (AML) blasts. In this study we performed a detailed characterization of VEGF effects on native human AML blasts derived from a large group of consecutive AML patients with high blast counts in peripheral blood. Exogenous VEGF had divergent effects on spontaneous proliferation and cytokine-dependent (GM-CSF, G-CSF, IL-3) proliferation. Increased, decreased, or unaltered proliferation was observed in the presence of VEGF for various patients, and the VEGF effect differed even in the same patient depending on which exogenous cytokine being present together with VEGF. Similarly, increased, decreased or unaltered interleukin-1beta (IL-1beta) and IL-6 secretion was detected when VEGF was added, and for certain patients the effect of VEGF differed between IL-1beta and IL-6. Exogenous VEGF could also modulate proliferation and differentiation of clonogenic AML progenitors. Constitutive AML blast secretion of VEGF was detected for 40% of patients. Leptin, Flt3-L, IL-4, IL-10, and IL-13 had divergent effects on VEGF release by AML blasts. These results suggest that VEGF can modulate AML blast functions in vivo for a subset of patients. Furthermore, the detection of VEGF in peripheral blood stem cell (PBSC) autografts suggests that VEGF may influence the proliferation and possibly also the survival of contaminating AML cells in PBSC autografts. We conclude that VEGF may influence the functional characteristics of AML cells. Our results suggest that VEGF is important in leukemic hematopoiesis, and the detection of VEGF in PBSC autografts indicates that VEGF may influence the functional phenotype of contaminating AML cells in these grafts.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 045925223

Download citation: RISBibTeXText

PMID: 11276362

DOI: 10.1089/152581601750098291


Related references

Coculture of native human acute myelogenous leukemia blasts with fibroblasts and osteoblasts results in an increase of vascular endothelial growth factor levels. European Journal of Haematology 74(1): 24-34, 2005

Effects of insulin-like growth factor on proliferation and cytokine secretion by acute myelogenous leukemia blasts. Experimental Hematology 25(8): 853, 1997

In vitro effects of insulin-like growth factor-1 (IGF-1) on proliferation and constitutive cytokine secretion by acute myelogenous leukemia blasts. European Journal of Haematology 62(3): 191-198, 1999

Platelet-derived growth factor (PDGF) in human acute myelogenous leukemia: PDGF receptor expression, endogenous PDGF release and responsiveness to exogenous PDGF isoforms by in vitro cultured acute myelogenous leukemia blasts. European Journal of Haematology 66(6): 365-376, 2001

Effects of chemokines on endothelial transmigration of acute myelogenous leukemia blasts. Blood 94(10 Suppl. 1 Part 1): 437a, 1999

Antiangiogenic Therapy in Acute Myelogenous Leukemia: Targeting of Vascular Endothelial Growth Factor and Interleukin 8 as Possible Antileukemic Strategies. Current Cancer Drug Targets 5(4): 229-248, 2005

Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Current Cancer Drug Targets 5(4): 229-248, 2005

Effect of thalidomide and arsenic trioxide on the release of tumor necrosis factor-α and vascular endothelial growth factor from the KG-1a human acute myelogenous leukemia cell line. Oncology Letters 1(4): 663-667, 2010

Effects of acute myelogenous leukemia blasts on platelet release of soluble P-selectin and platelet-derived growth factor. Platelets 9(6): 352-358, 1998

Graft vs leukemia hla identical acute myelogenous leukemia blasts and t cell growth factor can activate minor locus reactive t cells in vitro. Journal Of Cellular Biochemistry Supplementt A: 69, 1983

Timed Sequential Therapy of Relapsed and Refractory Adult Acute Myelogenous Leukemia with the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab. Blood 100(11): Abstract No 744, 2002

Retroviral transduction of acute myelogenous leukemia blasts using the low affinity nerve growth factor receptor as a membrane reporter. Proceedings of the American Association for Cancer Research Annual Meeting 37: 341, 1996

Gene transfers of vascular endothelial growth factor-A, vascular endothelial growth factor-B, vascular endothelial growth factor-C, and vascular endothelial growth factor-D have no effects on atherosclerosis in hypercholesterolemic low-density lipoprotein-receptor/apolipoprotein B48-deficient mice. Circulation 112(9): 1347-1352, 2005

Participation of the cytokines interleukin 6, tumor necrosis factor-alpha, and interleukin 1-beta secreted by acute myelogenous leukemia blasts in autocrine and paracrine leukemia growth control. Journal of Clinical Investigation 84(2): 451-457, 1989

Fluctuations of serum vascular endothelial and basic fibroblast growth factors in adults with acute myelogenous and acute lymphoblastic leukemia. Annals of Hematology 83(Suppl. 1): S16, 2004